Right now, venture capital firms are struggling with the impact of a persistently anemic biotech market. But if past downturns are any indication, some VCs will steer out of the slump into brighter times.
The story of one fund overseen by The Column Group, a firm profiled in the 2023 edition of “Ranking biotech’s top venture capital firms,” STAT’s annual report on VC performance, shows how that might happen. READ MORE